230 related articles for article (PubMed ID: 26503945)
1. Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
Podo F; Santoro F; Di Leo G; Manoukian S; de Giacomi C; Corcione S; Cortesi L; Carbonaro LA; Trimboli RM; Cilotti A; Preda L; Bonanni B; Pensabene M; Martincich L; Savarese A; Contegiacomo A; Sardanelli F
Clin Cancer Res; 2016 Feb; 22(4):895-904. PubMed ID: 26503945
[TBL] [Abstract][Full Text] [Related]
2. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
3. Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
Møller P; Stormorken A; Jonsrud C; Holmen MM; Hagen AI; Clark N; Vabø A; Sun P; Narod SA; Mæhle L
Breast Cancer Res Treat; 2013 May; 139(1):155-61. PubMed ID: 23615785
[TBL] [Abstract][Full Text] [Related]
4. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
[TBL] [Abstract][Full Text] [Related]
6. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
Domagala P; Hybiak J; Cybulski C; Lubinski J
Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.
Wong-Brown MW; Meldrum CJ; Carpenter JE; Clarke CL; Narod SA; Jakubowska A; Rudnicka H; Lubinski J; Scott RJ
Breast Cancer Res Treat; 2015 Feb; 150(1):71-80. PubMed ID: 25682074
[TBL] [Abstract][Full Text] [Related]
8. Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers.
Tung N; Gaughan E; Hacker MR; Lee LJ; Alexander B; Poles E; Schnitt SJ; Garber JE
Breast Cancer Res Treat; 2014 Jul; 146(1):175-82. PubMed ID: 24839033
[TBL] [Abstract][Full Text] [Related]
9. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
Zugazagoitia J; Pérez-Segura P; Manzano A; Blanco I; Vega A; Custodio A; Teulé A; Fachal L; Martínez B; González-Sarmiento R; Cruz-Hernández JJ; Chirivella I; Garcés V; Garre P; Romero A; Caldés T; Díaz-Rubio E; de la Hoya M
Breast Cancer Res Treat; 2014 Nov; 148(2):415-21. PubMed ID: 25342642
[TBL] [Abstract][Full Text] [Related]
10. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
[TBL] [Abstract][Full Text] [Related]
11. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
Hartman AR; Daniel BL; Kurian AW; Mills MA; Nowels KW; Dirbas FM; Kingham KE; Chun NM; Herfkens RJ; Ford JM; Plevritis SK
Cancer; 2004 Feb; 100(3):479-89. PubMed ID: 14745863
[TBL] [Abstract][Full Text] [Related]
12. Mammographic, US, and MR imaging phenotypes of familial breast cancer.
Schrading S; Kuhl CK
Radiology; 2008 Jan; 246(1):58-70. PubMed ID: 18096529
[TBL] [Abstract][Full Text] [Related]
13. A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients.
Seong MW; Kim KH; Chung IY; Kang E; Lee JW; Park SK; Lee MH; Lee JE; Noh DY; Son BH; Park HL; Cho SI; Park SS; ; Kim SW
Breast Cancer Res Treat; 2014 Jul; 146(1):63-9. PubMed ID: 24894343
[TBL] [Abstract][Full Text] [Related]
14. Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis.
Tun NM; Villani G; Ong K; Yoe L; Bo ZM
Clin Genet; 2014 Jan; 85(1):43-8. PubMed ID: 24000781
[TBL] [Abstract][Full Text] [Related]
15. Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.
Pellegrino B; Bella M; Michiara M; Zanelli P; Naldi N; Porzio R; Bortesi B; Boggiani D; Zanoni D; Camisa R; Neri TM; Pinto C; Musolino A
Acta Biomed; 2016 May; 87(1):54-63. PubMed ID: 27163896
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
Tian T; Shan L; Yang W; Zhou X; Shui R
Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
[TBL] [Abstract][Full Text] [Related]
17. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
[TBL] [Abstract][Full Text] [Related]
18. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
[TBL] [Abstract][Full Text] [Related]
19. The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan.
Murakami W; Tozaki M; Nakamura S; Ide Y; Inuzuka M; Hirota Y; Murakami K; Takahama N; Ohgiya Y; Gokan T
Breast Cancer; 2019 Sep; 26(5):552-561. PubMed ID: 30820924
[TBL] [Abstract][Full Text] [Related]
20. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
Obdeijn IM; Winter-Warnars GA; Mann RM; Hooning MJ; Hunink MG; Tilanus-Linthorst MM
Breast Cancer Res Treat; 2014 Apr; 144(3):577-82. PubMed ID: 24567197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]